Skip to main content
. 2018 Feb 28;16:47. doi: 10.1186/s12967-018-1421-y

Fig. 3.

Fig. 3

Apatinib shows preferential cytotoxic activity against primary adult ALL cells while sparing normal PBMCs. The percentage of apoptotic cells (Annexin V+) of primary ALL patients (a) and peripheral blood or bone marrow of healthy donors (b) after exposure to indicated doses of Apatinib for 48 h. *P < 0.05; **P < 0.01